» Articles » PMID: 33803065

Assessing the Need for Multiplex and Multifunctional Tick-Borne Disease Test in Routine Clinical Laboratory Samples from Lyme Disease and Febrile Patients with a History of a Tick Bite

Overview
Date 2021 Apr 3
PMID 33803065
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Human polymicrobial infections in tick-borne disease (TBD) patients is an emerging public health theme. However, the requirement for holistic TBD tests in routine clinical laboratories is ambiguous. TICKPLEX PLUS is a holistic TBD test utilized herein to assess the need for multiplex and multifunctional diagnostic tools in a routine clinical laboratory. The study involved 150 specimens categorized into Lyme disease (LD)-positive ( = 48), LD-negative ( = 30), and febrile patients from whom borrelia serology was requested ( = 72, later "febrile patients") based on reference test results from United Medix, Finland. Reference tests from DiaSorin, Immunetics, and Mikrogen Diagnostik followed the two-tier LD testing system. A comparison between the reference tests and TICKPLEX PLUS produced 86%, 88%, and 87% positive, negative, and overall agreement, respectively. Additionally, up to 15% of LD and 11% of febrile patients responded to TBD related coinfections and opportunistic microbes. The results demonstrated that one (TICKPLEX PLUS) test can aid in a LD diagnosis instead of four tests. Moreover, TBD is not limited to just LD, as the specimens produced immune responses to several TBD microbes. Lastly, the study indicated that the screening of febrile patients for TBDs could be a missed opportunity at reducing unreported patient cases.

Citing Articles

Scrutinizing Clinical Biomarkers in a Large Cohort of Patients with Lyme Disease and Other Tick-Borne Infections.

Xi D, Garg K, Lambert J, Rajput-Ray M, Madigan A, Avramovic G Microorganisms. 2024; 12(2).

PMID: 38399784 PMC: 10893018. DOI: 10.3390/microorganisms12020380.


A Longitudinal Study of a Large Clinical Cohort of Patients with Lyme Disease and Tick-Borne Co-Infections Treated with Combination Antibiotics.

Xi D, Thoma A, Rajput-Ray M, Madigan A, Avramovic G, Garg K Microorganisms. 2023; 11(9).

PMID: 37763996 PMC: 10536678. DOI: 10.3390/microorganisms11092152.


Seroprevalence of Crimean Congo Hemorrhagic Fever Virus in Occupational Settings: Systematic Review and Meta-Analysis.

Ricco M, Baldassarre A, Corrado S, Bottazzoli M, Marchesi F Trop Med Infect Dis. 2023; 8(9).

PMID: 37755913 PMC: 10538165. DOI: 10.3390/tropicalmed8090452.

References
1.
Staunton C, Slokenberga S, Mascalzoni D . The GDPR and the research exemption: considerations on the necessary safeguards for research biobanks. Eur J Hum Genet. 2019; 27(8):1159-1167. PMC: 6777499. DOI: 10.1038/s41431-019-0386-5. View

2.
Tunev S, Hastey C, Hodzic E, Feng S, Barthold S, Baumgarth N . Lymphoadenopathy during lyme borreliosis is caused by spirochete migration-induced specific B cell activation. PLoS Pathog. 2011; 7(5):e1002066. PMC: 3102705. DOI: 10.1371/journal.ppat.1002066. View

3.
Chung Y, Zhang N, Wooten R . Borrelia burgdorferi elicited-IL-10 suppresses the production of inflammatory mediators, phagocytosis, and expression of co-stimulatory receptors by murine macrophages and/or dendritic cells. PLoS One. 2013; 8(12):e84980. PMC: 3868605. DOI: 10.1371/journal.pone.0084980. View

4.
Cook M, Puri B . Commercial test kits for detection of Lyme borreliosis: a meta-analysis of test accuracy. Int J Gen Med. 2016; 9:427-440. PMC: 5125990. DOI: 10.2147/IJGM.S122313. View

5.
Leeflang M, Ang C, Berkhout J, Bijlmer H, Van Bortel W, Brandenburg A . The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis. 2016; 16:140. PMC: 4807538. DOI: 10.1186/s12879-016-1468-4. View